Xanthine Oxidase Inhibition in Renal Transplant Recipients
Status:
Terminated
Trial end date:
2018-08-10
Target enrollment:
Participant gender:
Summary
Cardiovascular disease is the leading cause of mortality in kidney transplantation. The
enzyme xanthine oxidase may play an important role in the cardiovascular disease of kidney
transplant recipients. Inhibiting this enzyme with allopurinol may improve vascular health
and protects against cardiovascular complications.